First-Line Pembrolizumab-Combination Therapy for Advanced Squamous NSCLC: Real-World Outcomes at US Oncology Practices

被引：0
|
作者：
Liu, S. [1 ]
Rai, P. [2 ]
Wang, D. [2 ]
Hu, X. [2 ]
Schwarzenberger, P. [2 ]
机构：
[1] Georgetown Univ, Washington, DC USA
[2] Merck Co Inc, Kenilworth, NJ USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2022年 / 17卷 / 09期
关键词：
advanced squamous NSCLC; first-line pembrolizumab-chemotherapy; real-world settings;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP08.01-08
引用
收藏
页码：S383 / S384
页数：2
相关论文
共 50 条
  • [1] Pembrolizumab-combination therapy for previously untreated metastatic nonsquamous NSCLC: Real-world outcomes at US oncology practices
    Liu, Stephen V.
    Hu, Xiaohan
    Li, Yeran
    Zhao, Bin
    Burke, Thomas
    Velcheti, Vamsidhar
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [2] First-Line Pembrolizumab Plus Chemotherapy for Advanced Squamous NSCLC: Real-World Outcomes at U.S. Oncology Practices
    Liu, Stephen V.
    Rai, Pragya
    Wang, Dong
    Hu, Xiaohan
    Schwarzenberger, Paul Otto
    JTO CLINICAL AND RESEARCH REPORTS, 2023, 4 (02):
  • [3] Real-world outcomes of first-line pembrolizumab plus pemetrexed-carboplatin for metastatic nonsquamous NSCLC at US oncology practices
    Velcheti, Vamsidhar
    Hu, Xiaohan
    Piperdi, Bilal
    Burke, Thomas
    SCIENTIFIC REPORTS, 2021, 11 (01)
  • [4] Real-world outcomes of first-line pembrolizumab plus pemetrexed-carboplatin for metastatic nonsquamous NSCLC at US oncology practices
    Vamsidhar Velcheti
    Xiaohan Hu
    Bilal Piperdi
    Thomas Burke
    Scientific Reports, 11
  • [5] Real-world time on treatment (rwToT) analysis for first-line pembrolizumab combination therapy in advanced nonsquamous NSCLC
    Liu, S. V.
    Hu, X.
    Li, Y.
    Burke, T.
    Piperdi, B.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (04) : S756 - S757
  • [6] Pembrolizumab-combination therapy for NSCLC- effectiveness and predictive factors in real-world practice
    Knetki-Wroblewska, Magdalena
    Dziadziuszko, Rafal
    Jankowski, Tomasz
    Krawczyk, Pawel
    Bryl, Maciej
    Stencel, Katarzyna
    Wrona, Anna
    Bandura, Artur
    Smok-Kalwat, Jolanta
    Rok-Knapinska, Jolanta
    Szydziak-Zwierzynska, Kinga
    Rogoziewicz, Krzysztof
    Czyzewicz, Grzegorz
    Wojtowicz, Monika
    Wojtukiewicz, Marek
    Kalinka, Ewa
    Wysocki, Piotr J.
    Lobacz, Mateusz
    Milanowski, Janusz
    Pawlik, Hubert
    Kowalski, Dariusz M.
    Krzakowski, Maciej
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [7] REAL-WORLD TREATMENT PATTERNS AND CLINICAL OUTCOMES IN PATIENTS WITH METASTATIC NSCLC AFTER RECEIVING FIRST-LINE PEMBROLIZUMAB WITH PEMETREXED/PLATINUM CHEMOTHERAPY IN THE US ONCOLOGY NETWORK
    Goldschmidt, Jerome
    Annavarapu, Srinivas
    Venkatasetty, Divea
    Santorelli, Melissa
    Burke, Thomas
    Pennell, Nathan
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A974 - A975
  • [8] Real-world outcomes in patients with first-line and second-line therapy for advanced esophageal squamous cell carcinoma
    Ahn, Daniel
    Sidel, Michelle
    Panattoni, Laura
    Sacks, Naomi
    Hernandez, Jennifer
    Villacorta, Reginald
    FUTURE ONCOLOGY, 2022, 18 (30) : 3419 - 3433
  • [9] Pembrolizumab in Combination With Erlotinib or Gefitinib as First-Line Therapy for Advanced NSCLC With Sensitizing EGFR Mutation
    Yang, James Chih-Hsin
    Gadgeel, Shirish M.
    Sequist, Lecia VanDam
    Wu, Chien-Liang
    Papadimitrakopoulou, Vassiliki A.
    Su, Wu-Chou
    Fiore, Joseph
    Saraf, Sanatan
    Raftopoulos, Harry
    Patnaik, Amita
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (03) : 553 - 559
  • [10] REAL-WORLD USE OF PEMBROLIZUMAB COMBINATION REGIMENS IN FIRST-LINE RECURRENT/METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA
    Black, Christopher
    Wang, Liya
    Ramakrishnan, Karthik
    Goto, Daisuke
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A832 - A832
12345